©2024 Stanford Medicine
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
Not Recruiting
Trial ID: NCT01093326
Purpose
This study is an extension to the study AC-058B201 and will investigate the long-term safety,
tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple
sclerosis.
Official Title
Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis
Stanford Investigator(s)
Y. Joyce Liao, MD, PhD
Stanford Medicine Professor of Ophthalmology and Professor of Neurology
Eligibility
Inclusion Criteria:
1. Patients who completed study treatment at their regular Week 24 (End of treatment)
visit within the core study AC-058B201.
2. Signed informed consent for participating in the extension study.
Exclusion Criteria:
1. Any clinically relevant medical or surgical condition, which, in the opinion of the
investigator, would put the patient at risk by participating in the extension study.
Intervention(s):
drug: Ponesimod 10 mg
drug: Ponesimod 20 mg
drug: Ponesimod 40 mg
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Angela Campbell
(650) 721-6188